Form 4: C4 Therapeutics Executive Kelly Schick Reports Stock Transactions
SEC Form 4 Filing
Kelly Schick, Chief People Officer at C4 Therapeutics, reports acquisition and disposal of common stock and stock options.
Summary
- Kelly Schick, Chief People Officer of C4 Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On February 13, 2025, 1,735 shares of common stock were disposed of at $3.2 per share to cover tax obligations related to vesting RSUs.
- On February 14, 2025, 56,500 RSUs were acquired at $0.
- An additional 2,368 shares of common stock were disposed of at $3.18 per share to cover tax obligations related to vesting RSUs on February 14, 2025.
- Also on February 14, 2025, Schick acquired 84,700 stock options with an exercise price of $3.18, expiring on February 13, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing primarily reflects routine stock transactions related to executive compensation and tax obligations. The acquisition of RSUs and stock options is a positive sign, but the disposal of shares to cover taxes is a normal occurrence.
Positives
- Acquisition of 56,500 RSUs indicates a long-term incentive for the reporting person.
- Acquisition of 84,700 stock options suggests confidence in the company's future performance.
Future Outlook
The RSUs vest in four equal annual installments starting February 14, 2026, and the stock options vest monthly over four years starting March 14, 2025, indicating a long-term incentive structure.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in beneficial ownership.
- Employees may be impacted by the vesting of RSUs and stock options.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Disposal of 1,735 shares of common stock for tax obligations. |
| 02/14/2025 | Acquisition of 56,500 RSUs and 84,700 stock options; disposal of 2,368 shares of common stock for tax obligations. |
| 02/14/2026 | First vesting date for the acquired RSUs. |
| 03/14/2025 | First vesting date for the acquired stock options. |
| 02/13/2035 | Expiration date for the acquired stock options. |
| 02/18/2025 | Date of Form 4 filing. |
Keywords
Form 4, C4 Therapeutics, CCCC, Kelly Schick, Chief People Officer, Beneficial Ownership, Stock Options, RSUs, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.